1-9 of 9
Lovely Goyal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Comparable to Autologous CAR T

Free
Sattva S. Neelapu, Rajneesh Nath, Javier Munoz, Michael Tees, David B. Miklos, Matthew J. Frank, Shahbaz A. Malik, Don Stevens, Chu Ri Shin, Arun Balakumaran, Lynn Loomis-Navale, Lovely Goyal, Anh Nguyen, Frederick L. Locke
Journal: Blood
Blood (2021) 138 (Supplement 1): 3878.
https://doi.org/10.1182/blood-2021-146038
Published: 2021
Journal Articles

ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing

Free
Lazaros J. Lekakis, Frederick L. Locke, Michael Tees, Sattva S. Neelapu, Shahbaz A. Malik, Mehdi Hamadani, Matthew J. Frank, Leslie L. Popplewell, Jeremy S. Abramson, Sven de Vos, Javier Munoz, Chu Ri Shin, Arun Balakumaran, Lynn Loomis-Navale, Lovely Goyal, Xiangdong Zhou, David B. Miklos
Journal: Blood
Blood (2021) 138 (Supplement 1): 649.
https://doi.org/10.1182/blood-2021-146045
Published: 2021
Journal Articles

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Free
Clinical Trials & Observations
Bijal D. Shah, Michael R. Bishop, Olalekan O. Oluwole, Aaron C. Logan, Maria R. Baer, William B. Donnellan, Kristen M. O’Dwyer, Houston Holmes, Martha L. Arellano, Armin Ghobadi, John M. Pagel, Yi Lin, Ryan D. Cassaday, Jae H. Park, Mehrdad Abedi, Januario E. Castro, Daniel J. DeAngelo, Adriana K. Malone, Raya Mawad, Gary J. Schiller, John M. Rossi, Adrian Bot, Tong Shen, Lovely Goyal, Rajul K. Jain, Remus Vezan, William G. Wierda
Journal: Blood
Blood (2021) 138 (1): 11–22.
https://doi.org/10.1182/blood.2020009098
Published: 2021
Includes: Supplemental data
Journal Articles

Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Free
Caron Jacobson, MD MMSc, Julio C. Chavez, MD, Alison R. Sehgal, MD, Basem M. William, MDMRCP, Javier Munoz, MD, Gilles Salles, MDPhD, Pashna N. Munshi, MD, Carla Casulo, MD, David Maloney, MD PhD, Sven de Vos, MD PhD, Ran Reshef, MD, Lori A. Leslie, MD, Ibrahim Yakoub-Agha, Olalekan O. Oluwole, MBBS, MPH, Henry C.H. Fung, MD, Joseph D. Rosenblatt, MD, John M. Rossi, MS, Lovely Goyal, PhD, Vicki Plaks, LLB, PhD, Yin Yang, MS, Jennifer Lee, BS, Wayne Godfrey, MD, Remus Vezan, MD PhD, Mauro P. Avanzi, MD PhD, Sattva S. Neelapu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-136834
Published: 2020
Journal Articles

Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)

Free
Sattva S. Neelapu, MD, Michael Dickinson, DMed Sci, Matthew L. Ulrickson, MD, Olalekan O. Oluwole, MBBS, MPH, Alex F. Herrera, MD, Catherine Thieblemont, MD PhD, Chaitra S. Ujjani, MD, Yi Lin, MD PhD, Peter A. Riedell, MD, Natasha Kekre, MD MPH, FRCPC, Sven de Vos, MD PhD, Yin Yang, MS, Francesca Milletti, PhD, Lovely Goyal, PhD, Jun Kawashima, MD, Julio C. Chavez, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 49.
https://doi.org/10.1182/blood-2020-134449
Published: 2020
Journal Articles

Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5

Free
Julio C. Chavez, MD, Caron A. Jacobson, MD, Alison R. Sehgal, MD, Sattva S. Neelapu, MD, David G. Maloney, MD PhD, Gilles Salles, MD PhD, Basem M. William, MDMRCP, Yin Yang, MS, Lovely Goyal, PhD, Justin Chou, PhD, Vicki Plaks, LLB, PhD, Mauro P. Avanzi, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 34.
https://doi.org/10.1182/blood-2020-135871
Published: 2020
Journal Articles

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

Free
Caron A. Jacobson, MD, Frederick L. Locke, MD, David B. Miklos, MD PhD, Julie M. Vose, MD MBA, Yi Lin, MD PhD, Lihua E Budde, MD PhD, David G. Maloney, MD PhD, Samantha Jaglowski, MD MPH, Peter A. Riedell, MD, Lazaros J. Lekakis, MD, Miguel-Angel Perales, MD, Jenny J. Kim, MD MS, Jun Kawashima, MD, Yin Yang, MS, John M. Rossi, MS, Lovely Goyal, PhD, Sattva S. Neelapu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-136136
Published: 2020
Journal Articles

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)

Free
Sattva S Neelapu, MD, Mohamed A Kharfan-Dabaja, MDMBA, Olalekan O. Oluwole, MBBS, MPH, Patel Krish, MD, Ran Reshef, MDMSc, Peter A. Riedell, MD, Parveen Shiraz, MD, Patrick J. Stiff, MD, Jose Villasboas, MD, Lovely Goyal, PhD, Jun Kawashima, Francesca Milletti, PhD, Edward Oliva, Jennifer Sun, MS, Javier Munoz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4093.
https://doi.org/10.1182/blood-2019-126369
Published: 2019
Journal Articles

Safety and Tolerability of Conatumumab in Combination with Bortezomib or Vorinostat in Patients with Relapsed or Refractory Lymphoma.

Free
Anas Younes, MD, Mark Kirschbaum, MD, Lubomir Sokol, MD, PhD, Lorrin Yee, Jorge Romaguera, MD, Lovely Goyal, Cheng-Pang Hsu, Yuying Hwang, Kevin Gorski, Susan Wong, Darrin M. Beaupre, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1708.
https://doi.org/10.1182/blood.V114.22.1708.1708
Published: 2009